Cyclerion Therapeutics Files 8-K

TL;DR

Cyclerion filed a routine 8-K, no big news.

AI Summary

Cyclerion Therapeutics, Inc. filed an 8-K on December 1, 2025, reporting an event under 'Other Events'. The filing does not contain specific financial transactions or material business updates beyond the standard reporting requirement.

Why It Matters

This filing indicates Cyclerion Therapeutics, Inc. has submitted a routine report to the SEC, but it does not disclose any new material information that would immediately impact investors.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report and does not contain information that suggests an immediate change in risk for the company.

Key Players & Entities

• Cyclerion Therapeutics, Inc. (company) — Registrant
• December 1, 2025 (date) — Date of earliest event reported
• Massachusetts (location) — State of incorporation
• 001-38787 (other) — SEC File Number
• 83-1895370 (other) — IRS Employer Identification Number
• 245 First Street , 18th Floor Cambridge , Massachusetts 02142 (address) — Principal executive offices
• (857) 327-8778 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $1.0 million — ical trial in the U.S. for a product, a $1.0 million regulatory milestone payment would be d

Filing Documents

• d48096d8k.htm (8-K) — 23KB
• 0001193125-25-304067.txt ( ) — 134KB
• cycn-20251201.xsd (EX-101.SCH) — 3KB
• cycn-20251201_lab.xml (EX-101.LAB) — 18KB
• cycn-20251201_pre.xml (EX-101.PRE) — 11KB
• d48096d8k_htm.xml (XML) — 4KB

From the Filing

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2025 CYCLERION THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Massachusetts 001-38787 83-1895370 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification Number) 245 First Street , 18th Floor Cambridge , Massachusetts 02142 (Address of principal executive offices, including Zip Code) Registrant's telephone number, including area code: (857) 327-8778 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, no par value CYCN The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item8.01 Other Events On December 1, 2025, Akebia Therapeutics, Inc. ("Akebia") publicly announced that it has recently initiated Phase 2 clinical trials for the treatment of focal segmental glomerulosclerosis ("FSGS") using Praliciguat, an oral soluble guanylate cyclase licensed to Akebia by Cyclerion Therapeutics, Inc. (Cyclerion"). Pursuant to the terms of Amendment #1 to the License Agreement by and between Akebia and Cyclerion, upon initiation (defined as first patient dosed) of a Phase 2 clinical trial in the U.S. for a product, a $1.0 million regulatory milestone payment would be due to Cyclerion. At this time, Akebia has stated that it currently expects to dose its first patient with Praliciguat in the Phase II study in 2026. Disclaimer on Forward-Looking Statements This current report on Form 8-K contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding planned Phase 2 clinical studies which Akebia has announced it has recently initiated for use of Praliciguat in treating FSGS and if and when Akebia will begin dosing patients in the Phase II clinical trial. Statements regarding the Company's business and announcements by Akebia regarding the use of Praliciguat in FSGS that are not historical facts may be "forward-looking statements" that involve risks and uncertainties. Forward-looking statements are based on management's current, preliminary expectations (based on information publicly disclosed by Akebia) and are subject to risks and uncertainties that could cause actual results to differ from the results predicted. These risks and uncertainties include risks and uncertainties included under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K, as updated by its subsequent filings with the SEC, all of which are available on the Company's investor relations website at http://www.cyclerion.com and on the SEC's website at http://www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made, or to reflect the occurrence of unanticipated events. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Cyclerion Therapeutics, Inc. Dated: December 1, 2025 By: /s/ Regina Graul Name: Regina Graul Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR